ABSTRACT
OBJECTIVE:To establish the evaluation index system that is suitable for biological pharmaceutical industry cluster competitiveness,and provide reference for the evaluation of biological pharmaceutical industry cluster competitiveness in Jiangsu province. METHODS:Biological pharmaceutical industry cluster enterprises in Jiangsu province were selected as research samples. Through the questionnaires,the grey multi-index evaluation method was used to determine weight set,establish evaluation sample matrix,and evaluate and analyze 3 first-level indexes(8 second-level indexes,and 23 tertiary-level indexes),such as the innova-tion knowledge spillover,innovation network and social capital,etc. RESULTS & CONCLUSIONS:The financial indicators such as investment intensity of biological pharmaceutical industry cluster in Jiangsu province were low,and there was a shortage of funds problem;new drug patents of independent intellectual property rights were insufficient,and lacked of protection of intellectu-al property rights,there was an independent innovation motivation problem;profitability indexes such as the rate of product sales were low,there was a problem of low industrialization of scientific research;social culture score in social capital level was not high,there was a problem of strengthening soft environment such as the binding biological innovation public service platform. It is suggested to strengthen the cooperation among cluster enterprises and scientific research institutions,and improve enterprise innova-tion power;improve the mechanism of biological innovation and the level of industrialization of scientific research achievements;and actively guide the various types of biological innovation public service platform to participate in the construction of the soft en-vironment of the cluster.
ABSTRACT
OBJECTIVE: To systematically analyse and comb the relationship and co-influence between service and biological pharmaceutical industry, and to provide data support for the current Chinese bio-pharmaceutical industrial policy, as well as a reference of innovation and development for biological pharmaceutical enterprises. METHODS: The biological pharmaceutical industry data of National Innovation Fund from 2005 to 2012 was analyzed, summarized, and concluded. RESULTS: High profitable service-oriented enterprises can actively attract social capital investment; service-oriented enterprise, born from biopharmaceutical industry chain, can form high growth of biopharmaceutical services; the regional biopharmaceutical services have almost shaped well, with distinctive characteristics. CONCLUSION: Based on the data facts and quantitative analysis, we put forward a new model of biopharmaceutical industry chain under the perspective of service, which has vital significance on parsing the relationship between service and biological pharmaceutical industry, promoting industry amalgamation and industry conversion, and directing biological pharmaceutical enterprises for innovative development.